<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7600111</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5310</journal-id>
<journal-id journal-id-type="nlm-ta">J Neurosci Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci. Res.</journal-id>
<journal-title-group>
<journal-title>Journal of neuroscience research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0360-4012</issn>
<issn pub-type="epub">1097-4547</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27376697</article-id>
<article-id pub-id-type="pmc">5214992</article-id>
<article-id pub-id-type="doi">10.1002/jnr.23797</article-id>
<article-id pub-id-type="manuscript">NIHMS792437</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Defective Phosphoinositide Metabolism in Autism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gross</surname>
<given-names>Christina</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Neurology, Cincinnati Childrenâ€™s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA</aff>
<aff id="A2"><label>2</label>Department of Pediatrics, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH 45229, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Christina Gross, 3333 Burnet Avenue, Cincinnati, OH 45229, Phone: 513-636-3493, Fax: 513-636-1888, <email>christina.gross@cchmc.org</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>CONFLICT OF INTEREST</bold>
</p>
<p>The author declares no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>8</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>04</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>95</volume>
<issue>5</issue>
<fpage>1161</fpage>
<lpage>1173</lpage>
<!--elocation-id from pubmed: 10.1002/jnr.23797-->
<abstract id="Abs1">
<p id="P1">Phosphoinositides are essential components of lipid membranes and crucial regulators of many cellular functions, including signal transduction, vesicle trafficking, membrane receptor localization and activity, and the determination of membrane identity. These functions depend on the dynamic and highly regulated metabolism of phosphoinositides and require finely balanced activity of specific phosphoinositide kinases and phosphatases. There is increasing evidence from genetic and functional studies that these enzymes are often dysregulated or mutated in autism spectrum disorders; in particular, phosphoinositide 3-kinases and their regulatory subunits appear to be affected frequently. Examples of autism spectrum disorders with defective phosphoinositide metabolism are Fragile X syndrome and autism disorders associated with mutations in the phosphoinositide 3-phosphatase PTEN, but recent genetic analyses also suggest that select non-syndromic, idiopathic forms of autism may have altered activity of phosphoinositide kinases and phosphatases. Isoform-specific inhibitors for some of the phosphoinositide kinases have already been developed for cancer research and treatment, and a few are being evaluated for the use in humans. Taken together, this offers exciting opportunities to explore altered phosphoinositide metabolism as therapeutic target in individuals with certain forms of autism. This review summarizes genetic and functional studies identifying defects in phosphoinositide metabolism in autism and related disorders, describes published preclinical work targeting phosphoinositide 3-kinases in neurological disorders, and discusses the opportunities and challenges ahead to translate these findings from animal models and human cells into clinical application in humans.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Graphical Abstract</title>
<p id="P43">
<graphic orientation="portrait" position="anchor" xlink:href="nihms792437u1.jpg"></graphic></p>
<p id="P3">Regulated phosphoinositide metabolism is crucial for cellular function. Several phosphoinositide kinases and phosphatases are mutated or dysfunctional in autism spectrum disorders and other neurodevelopmental diseases, suggesting a shared molecular defect with treatment potential.</p>
</abstract>
<kwd-group>
<kwd>phosphoinositide 3-kinase</kwd>
<kwd>PTEN</kwd>
<kwd>signal transduction</kwd>
<kwd>schizophrenia</kwd>
<kwd>autism</kwd>
<kwd>biomarker</kwd>
<kwd>therapeutic strategy</kwd>
<kwd>Fragile X syndrome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>